The authors reviewed case reports of patients presenting to an advanced medical assessment and resuscitation service at 15 music events over 22 days from June 2018 through March 2019 around Australia. Event size ranged from 4,000 to 57,500 participants. Events observed had a mean patient presentation rate (PPR) of 0.83% (SD = 0.59%) and mean transport to hospital rate (TTHR) of 1.89 (SD = 0.92) per 10,000. Two-hundred and twenty-one cases were reviewed and tabulated for descriptive analysis.

Lower rates of traumatic injuries were seen compared to other case reports, and minor procedures represented a minor but important part of the team’s workload. Methylenedioxymethamphetamine (MDMA) use was reported by 33.0% of patients on the day of presentation; almost one-half of these reported a co-ingestion. Patients presenting after using MDMA were more likely to have an elevated temperature. Eight percent of patients presented with temperature above 38°C. Patients with an initial temperature above 38°C were more likely to require hospitalization. On-site electrocardiograph (ECG), blood gas, ultrasound, and urinalysis were found to be useful in decision support. In total, 29.8% of patients required sedation during their encounter; 2.7% required rapid sequence induction at the event. Mean observation time was 44 minutes, with longer observation required in MDMA and hallucinogen-related presentations.

The causes of high anion gap metabolic acidosis (HAGMA) are well described in the literature. However, sometimes more frequent causes of HAGMA cannot explain its occurrence.

In the case of HAGMA and severe neurological depression in the absence of other causes of HAGMA, clinicians should consider an intoxication with gamma-hydroxybutyrate (GHB) as a possible cause.

GHB is endogenous to the mammalian central nervous system (CNS). Synthetic GHB was initially used as an anesthetic but is now only licensed for medical use in a limited number of indications such as the treatment of narcolepsy. Because of its euphoric effects, it became popular for recreational use under the street names: Liquid Ecstasy, Georgia Home Boy, and Liquid G.

We describe the clinical case of a patient who suffered from severe neurological depression and HAGMA.

1,4-Butanediol (1,4-BD) is an industrial solvent that is metabolized to gamma-hydroxybutyrate (GHB), a gamma-aminobutyric acid agonist and central nervous system depressant. GHB and its analogues are popular drugs of abuse. Withdrawal from these agents is characterized by autonomic instability and altered mental status. We report a case of withdrawal from 1,4-BD lasting 6 days and complicated by new onset of seizures and rhabdomyolysis. In addition, we conducted a systematic review of the English literature pertaining to withdrawal from GHB, 1,4-BD and gamma-butyrolactone (GBL). Data collected from source articles included last use prior to symptom onset, clinical features on presentation, duration of symptoms and outcome. Twenty-seven studies with 57 episodes of withdrawal were included. Thirty-six cases (63%) involved GHB, 3 cases (5%) involved 1,4-BD and 18 (32%) involved GBL. The most common patient symptoms were tremor (67%), hallucinations (63%), tachycardia (63%) and insomnia (58%). Seizures and rhabdomyolysis each occurred in 7% of cases, but only 1 death occurred. Emergency physicians must consider withdrawal from these agents when patients present with clinical features suggestive of a sedative-hypnotic withdrawal syndrome.

Total intravenous anaesthesia (TIVA) using propofol, gamma-hydroxybutyrate (GHB) or midazolam in combination with sufentanil was investigated in 45 patients undergoing coronary artery bypass grafting (CABG). Anaesthesia was induced with sufentanil, etomidate and pancuronium. After endotracheal intubation, anaesthesia was continued with sufentanil (2 μg kg−1 h−1) for all patients. Patients were randomized to receive supplementary propofol (2 mg kg−1 h−1, n = 15), gamma-hydroxybutyrate (20 mg kg−1 h−1, n = 15) or midazolam (0.06 mg kg−1 h−1, n = 15). Haemodynamic measurements were performed after induction and at various times in the pre-bypass period. In the propofol group, a significant decrease in heart rate (HR 12%±3%), cardiac index (CI 23%±4%), mean arterial pressure (MAP 16%±3%) and left ventricular stroke work index (LVSWI 17%±4%) occurred until sternotomy was performed. With the exception of cardiac index, both midazolam and gamma-hydroxybutyrate produced similar haemodynamic effects: cardiac index was temporarily decreased (19%±4%) by midazolam and remained unchanged after gamma-hydroxybutyrate. In both groups, sternotomy was followed by temporary hypertension, associated with a significant rise in systemic vascular resistance. No electrocardiographical signs of ischaemia were observed in any patient. In the case of propofol and midazolam, gamma-hydroxybutyrate showed adequate haemodynamic stability especially after induction of anaesthesia and may also be a suitable agent for total intravenous anaesthesia in patients with coronary artery disease. However, during sternotomy, supplementary administration of opioids was required.